Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer
News | Prostate Cancer
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
GE HealthCare will deliver the Cyclotrons to ALISA’s laboratory facility in Midrand, South Africa early next year, giving patients in Africa access to medical advancements
News | PET Imaging
GE HealthCare and Axim Life Isotopes South Africa (ALISA) Collaborate to Expand Access to Molecular Imaging in South Africa and Drive Precision Care

April 28, 2023 — GE HealthCare to deliver two Cyclotrons next year, expanding South Africa’s capacity to produce ...

Time April 28, 2023
arrow
NorthStar Medical Radioisotopes has expanded its management team with the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations.
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

April 24, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 24, 2023
arrow
NorthStar Medical Radioisotopes has promoted Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies.
News | Molecular Imaging
NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies

April 13, 2023 —NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 13, 2023
arrow
New radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) provides powerhouse combination of capabilities and expertise to advance patient care
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

April 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 03, 2023
arrow
Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications
News | PET Imaging
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck

March 29, 2023 — Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to ...

Time March 29, 2023
arrow
RYZ101 positioned to be the first approved Actinium-225 radiopharmaceutical therapy for the industry
News | Radiopharmaceuticals and Tracers
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

March 20, 2023 — RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against ...

Time March 20, 2023
arrow
A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients
News | Radiopharmaceuticals and Tracers
Pluvicto Supply Shortage Update: What SNMMI is Doing

March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to ...

Time March 16, 2023
arrow
100-foot crane lifting Rhodotron TTE-300 HE Electron Beam Accelerator at NorthStar Medical Radioisotope's new Ac-225 Production facility in Beloit, Wisconsin (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Receives Electron Beam Accelerator for First-of-its-Kind, Commercial-scale U.S. Production of Important Therapeutic Radioisotope Actinium-225 (Ac-225)

March 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time March 03, 2023
arrow
Sponsored Content | Videos | Contrast Media
VIDEO: Talking Trends with Bracco: Investing in the Future of Radiology

Bracco Diagnostics and Guerbet recently announced they had formed a strategic, global collaboration for the research ...

Time February 27, 2023
arrow
18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

February 9, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 09, 2023
arrow
Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time January 11, 2023
arrow
Patients for Safer Nuclear Medicine calls NRC ruling a victory, notes work to protect patients is not over
News | Nuclear Imaging
Patient Coalition Applauds Federal Decision Impacting Nuclear Medicine Safety

January 2, 2023 — The federal agency that oversees the administration of nuclear medicine has announced that it will ...

Time January 02, 2023
arrow
Figure 1. The fat pad adjacent to the kneecap (Hoffa's fat pad, infrapatellar fat pad) can change in signal on MRI when the knee is inflamed. (A) Normal knee without signs of inflammation. (B) Arrow pointing on a circumscribed area with higher signal (bright lines) in the area of the fat pad (normally dark), which is indicative of a beginning inflammatory reaction. (C) The whole fat pad has a higher signal (light grey color with white lines), which is a sign of progressive inflammation of the knee joint.
News | RSNA
NSAIDs May Worsen Arthritis Inflammation

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
NorthStar Medical Radioisotopes’ Radiopharmaceutical CDMO in Beloit, Wis. (artist rendering). Upon completion, NorthStar will be first and only U.S. company housing commercial-scale, multi-radioisotope production and radiopharmaceutical development services on the same campus, enabling collaborating companies to realize logistical, regulatory and cost benefits. (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
The American Society of Nuclear Cardiology has issued an alert about possible supply disruptions
News | Radiopharmaceuticals and Tracers
Alert: Mo-99/Tc-99m Supply Disruptions Possible

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Time November 05, 2022
arrow
18F-rhPSMA-7.3 PET image showing prostate cancer spread beyond the prostate region (Photo courtesy of Blue Earth Diagnostics)
News | PET Imaging
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

November 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time November 02, 2022
arrow
The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy
News | PET Imaging
Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
The center will be equipped with a Cyclone KIUBE offering the highest production capacity with a PET cyclotron.
News | Radiopharmaceuticals and Tracers
ElsMed, Novatec and IBA Sign Contract to Install Radiopharmaceutical Production Center in Georgia

October 6, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time October 06, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now